Answers are grounded in this paper and cite their sources.
Hepatocellular carcinoma (HCC) is the most common liver cancer and a relevant global health problem. Immune checkpoint inhibitors (ICIs) represent the most effective systemic treatment for HCC. However, due to primary resistance, approximately 40% of HCC patients do not achieve a disease control with ICIs. Moreover, a similar proportion will experience disease progression after an initial response caused by secondary resistance. This review describes the mechanisms of primary and secondary resistance and reports the ongoing therapeutic strategies to overcome these obstacles.
No takes yet. Share an insight, caveat, or question.
Lorenzo et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: